specificity

The ability of a diagnostic test to correctly identify those without a disease, minimizing false positives.

In healthcare, biotechnology, and medical device investing, specificity measures a diagnostic test's ability to correctly identify individuals who do not have a specific disease or condition. It represents the proportion of true negatives out of all people who are genuinely healthy. A test with high specificity minimizes false-positive results, ensuring that healthy individuals are not mistakenly flagged as having a medical condition. For biotechnology investors evaluating clinical trial data or early-stage diagnostic companies, specificity is a critical commercial metric. While sensitivity measures how well a test catches actual cases, low specificity can ruin a product's market viability. If a diagnostic test generates too many false positives, it leads to unnecessary, expensive, and potentially invasive follow-up procedures, which can prevent regulatory approval or limit adoption by insurance providers and clinicians. When evaluating diagnostic stocks, investors must look at specificity and sensitivity together. A test that is 100% specific but has very low sensitivity is commercially useless because it misses actual sick patients. Conversely, a highly sensitive screening test with poor specificity will overwhelm the healthcare system with false alarms. Investors should look for diagnostic platforms that maintain high specificity thresholds to ensure strong pricing power and reimbursement pathways.

A biotechnology company conducts a clinical trial for a new colon cancer screening test on 2,000 patients who are known to be cancer-free. The test correctly identifies 1,960 of these patients as healthy (true negatives), but incorrectly flags 40 of them as having cancer (false positives). The specificity of the test is calculated as 1,960 / (1,960 + 40) = 1,960 / 2,000 = 0.98, or 98%.